Trial Profile
A Efficacy and Safety of Secukinumab in real-world clinical practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jun 2020
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis
- Focus Therapeutic Use
- 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 15 Jul 2018 New trial record